During a routine neck ultrasound for a 38-year-old man with hypothyroidism, a 1.2 cm hypoechoic nodule with microcalcifications is discovered in the left thyroid lobe. The patient is asymptomatic, and thyroid function tests are normal on levothyroxine. What is the most appropriate next step in management?

Explanation

## Evaluation of Thyroid Nodule with Suspicious Features **Key Point:** A hypoechoic nodule with microcalcifications meets criteria for ultrasound-guided FNAC, which is the standard next step for cytological diagnosis and risk stratification. ### Ultrasound Risk Stratification of Thyroid Nodules | Feature | Risk Level | Management | |---------|-----------|-------------| | Hyperechoic/isoechoic, smooth margins, no calcifications | Low | Ultrasound follow-up | | Hypoechoic, irregular margins, microcalcifications | Intermediate-High | FNAC indicated | | Taller-than-wide, heterogeneous, marked hypoechogenicity | High | FNAC ± core biopsy | | Comet-tail artifact, cystic changes | Very Low | Observation | **High-Yield:** Microcalcifications (especially punctate) and hypoechogenicity are suspicious for malignancy (particularly papillary thyroid carcinoma). These features mandate FNAC for cytological evaluation. ### Why FNAC is the Appropriate Next Step 1. **Diagnostic yield** - Provides cytological diagnosis (benign, atypia of undetermined significance [AUS], follicular neoplasm, suspicious for malignancy, malignant) - Guides surgical vs. conservative management - Cost-effective and minimally invasive 2. **Bethesda Classification for Thyroid Cytopathology** - Category I (Non-diagnostic): Repeat FNAC or core biopsy - Category II (Benign): Ultrasound follow-up - Category III (AUS): Repeat FNAC or molecular testing - Category IV (Follicular neoplasm): Lobectomy or total thyroidectomy - Category V (Suspicious for malignancy): Thyroidectomy - Category VI (Malignant): Thyroidectomy **Clinical Pearl:** The combination of hypoechogenicity and microcalcifications increases the pretest probability of malignancy to ~70–80%, making FNAC mandatory before any surgical decision. ### Decision Pathway for Thyroid Nodule Management ```mermaid flowchart TD A[Thyroid nodule detected on ultrasound]:::outcome --> B{Suspicious features?}:::decision B -->|No suspicious features| C[Ultrasound follow-up]:::action B -->|Suspicious features present| D[Ultrasound-guided FNAC]:::action D --> E{Bethesda category?}:::decision E -->|Benign/Non-diagnostic| F[Repeat ultrasound]:::action E -->|AUS/Follicular neoplasm| G[Molecular testing or repeat FNAC]:::action E -->|Suspicious/Malignant| H[Thyroidectomy]:::action ``` **Mnemonic — Suspicious Ultrasound Features (CHIME):** **C**alcifications (microcalcifications), **H**ypoechogenicity, **I**rregular margins, **M**arked vascularity, **E**ccentricity (taller-than-wide). ### Why Other Options Are Suboptimal - **Repeat ultrasound in 6 months:** Delays diagnosis in a nodule with intermediate-to-high suspicion features. Observation is appropriate for low-risk nodules, not for those with microcalcifications. - **Hormone suppression therapy:** Not evidence-based for nodules with suspicious features. TSH suppression may be considered for benign nodules to slow growth, but it does not replace cytological diagnosis. - **Immediate thyroidectomy:** Premature without cytological confirmation. Surgery should be reserved for confirmed or highly suspicious malignancy (Bethesda V or VI), not based on ultrasound features alone.